New scrutiny mechanism and re-designation of notified bodies in a much changed EU medtech regulatory landscape
This article was originally published in SRA
Executive Summary
The European Commission's much awaited proposals for a regulation on medical devices and another on IVDs contain far-reaching measures that will impact medtech companies and other industry stakeholders1-3.